Size | Price | Stock | Qty |
---|---|---|---|
250mg |
|
||
500mg |
|
||
1g |
|
||
2g |
|
||
5g |
|
||
10g |
|
||
Other Sizes |
|
Purity: ≥98%
Gemcitabine (formerly LY-188011, NSC-613327; LY188011, NSC613327; dFdC; dFdCyd; trade name: Gemzar), an approved antimetabolite anticancer drug, is a potent DNA synthesis inhibitor with potential antineoplastic activity. With IC50s of 50 nM, 40 nM, 18 nM, and 12 nM, respectively, it suppresses the growth of PANC1, MIAPaCa2, BxPC3, and Capan2 cells. Difluorodeoxycytidine di- and triphosphate (dFdCDP, dFdCTP) are the active metabolites of gemcitabine that are produced intracellularly. The deoxynucleotide pool available for DNA synthesis is reduced when dFdCDP inhibits ribonucleotide reductase.
Targets |
DNA synthesis
|
|
---|---|---|
ln Vitro |
|
|
ln Vivo |
|
|
Cell Assay |
In a 96-well plate, BxPC-3, MIA PaCa-2, and PANC-1 cells are seeded. Cells are treated for a further 24 or 48 hours with vehicle, DMAPT, and/or Gemcitabine after 24 hours. Using the Cell Death Detection ELISA, apoptosis is measured in relation to vehicle-treated cells by counting the quantity of cytoplasmic histone-associated DNA fragments.
|
|
Animal Protocol |
Female BALB/c nude mice
5 mg/kg i.p. |
|
References |
Molecular Formula |
C9H11F2N3O4
|
|
---|---|---|
Molecular Weight |
263.2
|
|
Exact Mass |
263.07
|
|
Elemental Analysis |
C, 41.07; H, 4.21; F, 14.44; N, 15.97; O, 24.31
|
|
CAS # |
95058-81-4
|
|
Appearance |
Solid powder
|
|
SMILES |
C1=CN(C(=O)N=C1N)[C@H]2C([C@@H]([C@H](O2)CO)O)(F)F
|
|
InChi Key |
SDUQYLNIPVEERB-QPPQHZFASA-N
|
|
InChi Code |
InChI=1S/C9H11F2N3O4/c10-9(11)6(16)4(3-15)18-7(9)14-2-1-5(12)13-8(14)17/h1-2,4,6-7,15-16H,3H2,(H2,12,13,17)/t4-,6-,7-/m1/s1
|
|
Chemical Name |
4-amino-1-[(2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one
|
|
Synonyms |
|
|
HS Tariff Code |
2934.99.9001
|
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
|
---|
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 3.7994 mL | 18.9970 mL | 37.9939 mL | |
5 mM | 0.7599 mL | 3.7994 mL | 7.5988 mL | |
10 mM | 0.3799 mL | 1.8997 mL | 3.7994 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT03507491 | Active Recruiting |
Drug: Gemcitabine Drug: Nab-paclitaxel |
Cancer | Emory University | August 27, 2018 | Phase 1 |
NCT05093322 | Active Recruiting |
Drug: Surufatinib in combination with Gemcitabine |
Solid Tumor Lymphoma |
Hutchmed | November 30, 2021 | Phase 1 Phase 2 |
NCT04634539 | Active Recruiting |
Drug: Gemcitabine Drug: Nab-paclitaxel |
Pancreatic Ductal Adenocarcinoma Pancreatic Cancer |
Jun Gong, MD | May 13, 2021 | Phase 1 |
NCT03520790 | Active Recruiting |
Drug: Gemcitabine Drug: Nab-paclitaxel |
Pancreatic Cancer | Dana-Farber Cancer Institute | December 5, 2018 | Phase 1 Phase 2 |
NCT00479128 | Active Recruiting |
Drug: Bortezomib Drug: Gemcitabine |
Solid Tumor Urethral Cancer |
M.D. Anderson Cancer Center | September 28, 2006 | Phase 1 |